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Clinical trials and biostatistics workshop: introduction and 
overview
Crowley, John 
Cancer Research And Biostatistics, Seattle, WA, USA
This unique workshop was designed to bring together clinicians and 
statisticians to discuss current problems and potential solutions to issues 
in the design and analysis of lung cancer clinical trials and translational 
science. Each of the afternoon sessions pairs an oncologist with a bio-
statistician (some also have a formal discussant) to present a particular 
issue and approach. Two evening panels explore opportunities for lung 
cancer trials in Asia, and different models for clinical trial conduct.
Many of the current issues arise because of the development of newer, 
targeted therapies. The traditional phase II endpoint of tumor shrinkage 
may no longer be appropriate in such settings, and there may not be 
good historical data on newer endpoints such as disease control rate, 
so new phase II and phase II/III designs are needed. In addition, the 
degree to which therapies are targeted (and targets can be measured) 
has implications for the design of phase III trials. 
The ability to measure thousands of gene expression levels, gene vari-
ants or gene products brings with it the challenge of sorting through 
these high dimensional data sets to identify which patients will beneﬁt 
from particular therapies. The goal is to use genetic characteristics of 
the tumor and/or the host to tailor therapy.
Finally, the hope persists that the patient’s immune system can be 
enhanced and used to ﬁght cancer. This ﬁeld of immunotherapy also 
raises particular issues of clinical trial design.
WS-02 Biostatistics & Clinical Design Workshop, Sat, Sept 1, 13:00-18:00
Phase II Trials - endpoints, when to randomize
Zee, Benny 
Department of Clinical Oncology, The Chinese University of Hong 
Kong, Hong Kong, China
The primary objective of phase II trials is to screen a new agent or regi-
men for efﬁcacy and to provide estimates of its level of activity. In this 
workshop we will discuss commonly used endpoints such as complete 
plus partial response rate (overall response rate) and their correspond-
ing analysis and interpretation. The use of multiple-stage design to 
minimize increase the efﬁciency of screening will be discussed. The 
importance in the design of phase II trials to minimize the chance that a 
truly active agent is erroneously rejected will also be discussed. There 
are circumstances that randomized phase II trial may be appropriate 
and its correct interpretation will be discussed. 
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Designs with targeted therapies
West, Howard 
Swedish Cancer Institute, Seattle, WA, USA
The study of targeted therapies in oncology requires consideration 
of several features that are unique to this class of agents. Trials of 
molecularly targeted therapies need to carefully assess whether it is 
appropriate to restrict the study of a targeted therapy to a population 
with a molecular variable that may be particularly relevant to a targeted 
therapy, or whether it is more appropriate to open the trial to a broader 
population that may experience a less consistent and robust improve-
ment in clinical endpoints. Designs of trials with targeted therapies may 
also need to redeﬁne the importance of such endpoints as maximum 
tolerated dose versus minimal effective dose, and of objective response 
versus disease control/non-progression. Trials designed as a “window 
of opportunity” allow for the rapid testing of a targeted therapy with a 
biological endpoint, while other trials with this design may incorporate 
novel endpoints such as metabolic imaging to assess results rapidly. 
Examples of clinical trials with targeted therapies in lung cancer also 
illustrate how early use of combinations of conventional chemotherapy 
and targeted therapy may obfuscate the contribution of the molecular 
therapy or may even produce antagonistic combinations, and of how a 
cross-over design may introduce new challenges in the interpretation 
of the contribution of a novel targeted therapy. Finally, multi-targeted 
single agents and combinations of different targeted therapies raise 
additional questions in clinical trial design of how to optimize efﬁcacy, 
minimize safety risks, and evaluate the clinical beneﬁt of regimens 
compared with traditional standards using more conventional agents.
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Novel clinical trial design applying Bayesian adaptive 
randomization for targeted therapy in lung cancer - A step toward 
personalized medicine
Lee, J. Jack 
Department of Biostatistics, M. D. Anderson Cancer Center, Houston, 
TX, USA
Background: With the advancement in the understanding of multiple 
signaling pathways associated with lung cancer, many targeted thera-
pies have been developed. Utilization of molecularly targeted agents 
can inhibit these speciﬁc aberrant pathways, hence, lead to clinical 
efﬁcacy. The targeted agents, however, may not work for everyone. 
Biomarkers expressions can be used as indicators for the aberrant 
signaling to identify effective targeted therapy. Our major goals are to 
characterize the molecular signature of individual tumors, to offer best-
ﬁt targeted therapy to patients on the trial, and to identify promising 
targeted agents for future development. 
Methods: We have developed the “BATTLE” program, “Biomarker-
integrated Approaches of Targeted Therapy of Lung Cancer Elimina-
tion,” which consists of an umbrella screening trial and 4 parallel phase 
II targeted therapies trials (with erlotinib, sorafenib, vandetanib, and 
the combination of erlotinib and bexarotene) in advanced non-small 
cell lung cancer patients with prior chemotherapy. All patients will 
have biopsy samples taken for biomarker proﬁle assessment prior to 
the randomization, then they will be classiﬁed into one of the ﬁve 
marker groups: 1) EGFR mutation/ampliﬁcation, 2) K-ras and/or B-raf 
mutation, 3) VEGF and/or VEGFR expression, 4) RXR and/or cyclin 
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D1 expression, and 5) none of the above. The primary endpoint of this 
study is disease control rate (DCR), which is deﬁned as the fraction 
of patients who are in complete response, partial response, or stable 
disease state 8 weeks after randomization. The primary objective is to 
estimate and to test the DCR for each treatment arm given the patients’ 
biomarker proﬁles. The null DCR and target DCR are set at 0.3 and 
0.6, respectively. A total of 200 patients will be enrolled, stratiﬁed into 
one of the ﬁve marker groups, and then adaptively randomized into one 
of the four treatments. Design parameters were chosen to achieve 20% 
type I error and 90% power. The larger type I error rate was chosen to 
increase the power and to minimize the false negative rate in this phase 
II setting.
We apply the outcome-based adaptive randomization to allocate pa-
tients into treatments based on ongoing and interim observed data. The 
Bayesian ordinal probit model (Albert J and Chib S. Bayesian analysis 
of binary and polychotomous response date, Journal of the American 
Statistical Association, 88, 669-679, 1993) is used to characterize the 
DCR. Gibbs sampling was applied to compute the posterior prob-
abilities. Equal randomization will be performed for the ﬁrst cohort of 
patients, until at least one patient’s treatment outcome is available. Sub-
sequently, the newly enrolled patients will be adaptively randomized 
to one of the four treatment arms according to their biomarker proﬁle. 
The randomization rate is based on the updated posterior DCR from ac-
cumulated data in the trial. For each biomarker proﬁle, better perform-
ing arms will have higher randomization rates and vise versa. Early 
stopping rules are set so that low-performing arms may be suspended 
for new patients being randomized into the arms .
Results: Based on extensive simulation studies, the proposed design 
has the following desirable operating characteristics to: 1) recommend 
effective agents with high probability (80% for DCR=0.5 and 90% 
for DCR= 0.6); 2) recommend ineffective agents with low probability 
(<20% for DCR=0.3; 3) suspend ineffective agents with high probabil-
ity (>60%); and 4) treat more patients with effective agents according 
to their biomarker proﬁles. The Bayesian design incorporates prior 
data and ﬁndings from the current patients to update estimates of the 
treatment efﬁcacy for patients with different biomarker proﬁles. The 
design continues to “learn.” The estimates continue to improve as the 
trial moves forward. The model-based method is useful in combining 
the information gathered from all 20 treatments by marker subgroups to 
make better inference.
Discussion: The Bayesian AR design provides a smart and ethi-
cal design, which is ideally suitable for the development of targeted 
therapy. It can assist in identifying effective agents based on individual 
patients’ tumor biomarker proﬁle, thus providing the ability to treat 
more patients with effective therapies. Compared with the conventional 
approach, the Bayesian design can incorporate data from the literature 
and the interim results from the current trial to form better estimates 
of treatment efﬁcacy for patients in different biomarker proﬁles. It is a 
“smart” design which matches patients with right drugs based on the 
up-to-date information. The information continues to be reﬁned as the 
trial progresses. Important challenges remains to be addressed which 
include the following: 1) Prior speciﬁcations: The choice on how strong 
the prior should be to incorporate the prior information and allow-
ing borrowing strength across treatment and biomarker subgroups; 2) 
Adaptive randomization ratio: Patients with different biomarker proﬁle 
are adaptively randomly assigned to treatments based on the poste-
rior mean of the marginal DCRs. It is an open question on how much 
weight should be given to the posterior DCR; 3) Biased in estimating 
the population DCR. Adaptive randomization can cause bias in estima-
tion due to dependent sampling scheme. It is important to quantify and 
correct the bias; 4) Speciﬁcation on the early stopping rule. Stopping to 
randomize patients into ineffective treatments is desirable but stopping 
too early may result in false negative conclusion; 5) Missing biomarker 
information. In clinical settings, not every patient has a biopsiable 
tumor. In addition, an assessment of the entire biomarker panel may 
not be complete for some patients. Shall patients with no or partial 
biomarker results be enrolled in the study? If so, how? 6) Biomarker 
assessment, outcome evaluation, and accrual. To apply the biomarker 
driven, outcome based adaptive randomization; the time for biomarker 
assessment needs to be short. The time for outcome evaluation needs to 
be relatively short and the accrual cannot be too fast as well, so that the 
decision based on up-to-date data can provide appropriate guidance for 
subsequent patients; 7) Trial conduct. We have developed a database to 
capture the biomarker and outcome information in real time. Bayesian 
computation and the randomization algorithm were written in R. An 
integrated web-base application was built via web services. 
In the midst of many challenges, we have derived an adaptive random-
ization design to achieve our goals of identifying the effective agents 
for patients with different biomarker proﬁles and better treating patients 
on the trial. It is a step towards “personalized medicine.” With the 
growing medical knowledge and molecular/genomic biomarker tools, 
an efﬁcient and ﬂexible design, such as this, will enable us continue to 
learn more about the new agents’ clinical activities and their molecular 
underpinning in real time. Applying this knowledge, we will be able to 
provide better treatments to current and new patients. 
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Biostatistical and bioinformatics approaches in high dimensional 
data derived from high throughput assays: a consumer guide
Shyr, Yu 
Vanderbilt University School of Medicine, Nashville, TN, USA
Motivation: The last decade has seen a veritable explosion in the 
amount of raw information generated by molecular biologists world-
wide. Modern technology today allows the collection of biological 
information at an unprecedented level of detail and in increasingly 
vast quantities. To reap real knowledge from the mountains of data 
produced, however, requires interdisciplinary skills-a background not 
only in biology but also in biostatistics and the bioinformatics tools 
and techniques of data analysis. The motivation of this talk is to help 
the audience meet the challenges of genomic, e.g., microarray experi-
ment, and proteomic, e.g., M(S)ALDI-TOF experiments, research. 
The challenges of these researches include the experiment design, 
data pre-processing, quality control, data mining, pattern recognition, 
class comparison, model prediction, visualization, and interpretation. 
The talk builds the foundation in the biostatistics, bioinformatics, and 
data analysis tools needed by biologists and provides the overview of 
high throughput assays needed by statisticians, mathematicians, and 
bioinformaticians. 
Aims: There are six aims of this talk 
1. Introduction to the high throughput assays - today and tomorrow.
2. Issues of the experiment design of the high throughput assays.
3. Topics of the data pre-processing including the assessment of the 
quality control.
4. Methods of the data analysis: data mining, pattern recognition, class 
comparison, model prediction.
